| | Overall cohort () | Copeptin < 17.4 pmol/l () | Copeptin ≥ 17.4 pmol/l () | value |
| Baseline parameters and medical history | Age (years) | 63 (57–73) | 62 (56–69) | 65 (57–78) | 0.04 | Male sex | 100, 65% | 72, 65.5% | 28, 58.3% | 0.25 | BMI (kg/m2) | 28.7 (42.9–32.3) | 28 (25–32) | 29 (25–32) | 0.93 | CAD | 67, 44% | 50, 45.5% | 17, 35.4% | 0.17 | Hypertension | 114, 74% | 75, 68.2% | 39, 81.3% | 0.17 | Diabetes mellitus | 42, 27% | 28, 25.5% | 14, 29.2% | 0.72 | PAD | 4, 2.6% | 3, 2.7% | 1, 2.1% | 0.79 | Familial history of CAD | 21, 14% | 18, 16.4% | 3, 6.3% | 0.07 | Current smoker | 51, 33% | 38, 34.5% | 13, 27.1% | 0.28 | Past smoker | 31, 20% | 23, 20.9% | 8, 16.7% | 0.47 | Dyslipidemia | 67,44% | 49, 44.5% | 18, 37.5% | 0.31 | History of AMI | 46, 30% | 36, 32.7% | 10, 20.8% | 0.10 | History of PCI | 48, 31% | 36, 32.7% | 12, 25.0% | 0.27 | History of CABG | 7, 4.5% | 7, 6.4% | 0, 0% | 0.07 | History of stroke | 4, 2.6% | 3, 2.7% | 1, 2.1% | 0.79 | Baseline clinical status | Heart rate (beats/min) | 75 (66–88) | 70 (65–80) | 75 (70–85) | 0.07 | Systolic BP | 140 (123–160) | 140 (125–160) | 140 (120–160) | 0.54 | EF (%) | 55 (45–60) | 55 (45–60) | 55 (43–60) | 0.56 | NYHA class III or IV | 4, 2.6% | 1, 0.9% | 3, 6.3% | 0.06 | Killip class | | | | 0.50 | 1 | 139, 90% | 98, 89.1% | 41, 85.4% | | 2 | 14, 9.1% | 7, 6.4% | 7, 14.6% | | 3 | 1, 0.6% | 1, 0.9% | 0, 0% | | 4 | 0, 0% | 0, 0% | 0, 0% | | GRACE | 124 (104–146) | 120 (101–141) | 131 (111–167) | 0.03 | Laboratory parameters | Hs-TnT T0 (ng/l) | 33 (13–143) | 25 (11–125) | 68 (30–177) | 0.01 | Hs-TnT T6 (ng/l) | 75 (16–397) | 32 (13–247) | 234 (43–2284) | <0.001 | Hs-TnT max (ng/l) | 105 (23–530) | 52 (17–274) | 236 (74–2070) | <0.001 | CK-MB T0 (IU/l) | 20 (15–30) | 19 (14–28) | 22 (17–36) | 0.06 | CK-MB T6 (IU/l) | 21 (14–45) | 18 (13–32) | 33 (18–107) | <0.001 | CK-MB max (IU/l) | 27 (18–53) | 25 (17–42) | 42 (25–111) | <0.001 | NT-proBNP (pg/ml) | 350 (163–1074) | 289 (150–872) | 491 (223–1979) | 0.02 | CRP (mg/l) | 2.9 (1.3–5.5) | 3 (1–5) | 4 (2–7) | 0.03 | Leukocytosis (103/μl) | 8.4 (6.9–10.3) | 8 (6–9) | 10 (8–12) | <0.001 | Hemoglobin (g/dl) | 14 (13–15) | 14 (13–15) | 14 (13–15) | 0.34 | GFR (ml/min/1.73m2) | 92 (76–110) | 93 (77–115) | 90 (67–99) | 0.08 | In-hospital parameters | Diagnosis of CAD | 116, 75% | 83, 75.5% | 33, 68.8% | 0.11 | Medical therapy | 38, 25% | 25, 22.7% | 13, 27.1% | 0.64 | PCI | 90, 58% | 60, 54.5% | 30, 62.5% | 0.49 | CABG | 33, 21% | 25, 22.7% | 8, 16.7% | 0.33 | Catecholamines | 4, 2.6% | 0, 0% | 4, 8.3% | 0.003 | ASA | 141, 92% | 97, 88.2% | 44, 91.7% | 0.79 | DAPT | 99, 64% | 68, 61.8% | 31, 64.6% | 0.96 | β-Blocker | 134, 87% | 93, 84.5% | 41, 85.4% | 0.81 | ACE inhibitor | 126, 82% | 91, 82.7% | 35, 72.9% | 0.07 | Statin | 135, 88% | 95, 86.4% | 40, 83.3% | 0.26 | Diuretic | 45, 29% | 31, 28.2% | 14, 29.2% | 0.97 | Ca-blocker | 39, 25% | 27, 24.5% | 12, 25.0% | 0.98 | Nitroglycerin | 17, 11% | 12, 10.9% | 5, 10.4% | 0.89 | Final diagnosis | Unstable angina | 30, 20% | 27, 24.5% | 3, 6.3% | 0.005 | NSTEMI | 105, 68% | 65, 59.1% | 40, 83.3% | 0.007 |
|
|